Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 116

Sort by

Sort Order Select

Journal Articles

Transcriptomic signatures associated with deep molecular response to ropeginterferon alfa-2b in polycythemia vera

Seug Yun Yoon, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won June-Won, Soo-Mee Bang, Joon Seong Park, Yong Park, Young Hoon Park, Sung-Eun Lee

Blood (2025) 146 (Supplement 1): 2040.

https://doi.org/10.1182/blood-2025-2040

Published: 2025

Journal Articles

Clinical significance of earlier CHR achievement and long-term CHR maintenance in polycythemia vera patients treated with ropeginterferon alfa-2b

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Yunsuk Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Jong Wook Lee, Yong Park, Young Hoon Park

Blood (2025) 146 (Supplement 1): 5598.

https://doi.org/10.1182/blood-2025-5598

Published: 2025

Journal Articles

Rapid JAK2 V617F decline predicts response durability: Kinetics of JAK2 V617F in ropeginterferon alfa-2b treated polycythemia vera

Blood (2025) 146 (Supplement 1): 3819.

https://doi.org/10.1182/blood-2025-3819

Published: 2025

Journal Articles

Phase I/II study of zanubrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (ZR-ICE) in Relapsed/Refractory diffuse large B-cell lymphoma: Results of the Phase I portion

Hyungwoo Cho, Jaewon Hyung, Dong Won Baek, Ho Sup Lee, Hye Jin Kang, Gyeong-Won Lee, Jeong-Ok Lee, Myung-Won Lee, Sung-Nam Lim, Sung Yong Oh, Ho-Jin Shin, Kwai Han Yoo, Young Rok Do, Jae-Yong Kwak, Yong-pyo Lee, Deok-Hwan Yang, Dok Hyun Yoon

Blood (2025) 146 (Supplement 1): 3702.

https://doi.org/10.1182/blood-2025-3702

Published: 2025

Journal Articles

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

Blood (2025) 145 (24): 2914–2926.

https://doi.org/10.1182/blood.2024027336

Published: 2025

Includes: Supplemental data

Journal Articles

Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

Seok Jin Kim, SangEun Yoon, Ji Hyun Lee, Jeong-Ok Lee, Seong Hyun Jeong, Sung-Nam Lim, Ho-Jin Shin, Duck Hwan Yang, Won Seog Kim

Blood (2024) 144 (Supplement 1): 1683.

https://doi.org/10.1182/blood-2024-205026

Published: 2024

Journal Articles

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Blood (2024) 144 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2024-200397

Published: 2024

Journal Articles

Distinct Factors Influence on Complete Hematological Response Maintenance in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b: From a Phase 2 Study in South Korea

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Yunsuk Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 6673.

https://doi.org/10.1182/blood-2024-206881

Published: 2024

Journal Articles

Refining Symptom Response Criteria in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 6642.

https://doi.org/10.1182/blood-2024-206509

Published: 2024

Journal Articles

Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon

Seug Yun Yoon, Jong-Ho Won, Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Yunsuk Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 3170.

https://doi.org/10.1182/blood-2024-207042

Published: 2024

Journal Articles

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Blood (2024) 144 (Supplement 1): 5.

https://doi.org/10.1182/blood-2024-199718

Published: 2024

Journal Articles

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Blood (2024) 144 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2024-207033

Published: 2024

Journal Articles

Retrospective Analysis of Treatment Outcome Differences with and without Autologous Stem Cell Transplantation in Patients with Dialysis-Dependent Multiple Myeloma (DDMM): KMM2304 Study

Myung-Won Lee, Sung-Hoon Jung, Chang-Ki Min, Kihyun Kim, Ho-Young Yhim, Dok Hyun Yoon, Sang Min Lee, Ho-Jin Shin, Jae-Cheol Jo, Jongheon Jung, Yundeok Kim, Jae Hoon Lee, Ji Hyun Lee, Sung-Hyun Kim

Blood (2024) 144 (Supplement 1): 7074.

https://doi.org/10.1182/blood-2024-210665

Published: 2024

Journal Articles

Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 4296.

https://doi.org/10.1182/blood-2024-205069

Published: 2024

Journal Articles

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2023-180499

Published: 2023

Journal Articles

Multicenter Prospective Phase II Study of Rituximab Combined, Bortezomib, Lenalidomide, Dexamethasone Followed By Lenalidomide Maintenance (R-VRD) in Patients with Waldenstrom's Macroglobulinemia (KMM1803)

Ho Sup Lee, Dajung Kim, Sung-Hoon Jung, Je-Jung Lee, Kihyun Kim, Chang-Ki Min, Jae Hoon Lee, Won-Sik Lee, JiHyun Lee, Gyeong Won Lee, Min Kyoung Kim, Ho-Jin Shin, Hyo Jung Kim, Jun Ho Yi

Blood (2023) 142 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2023-180325

Published: 2023

Journal Articles

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Blood (2023) 142 (Supplement 1): 620.

https://doi.org/10.1182/blood-2023-173509

Published: 2023

Journal Articles

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Seok Jin Kim, Myung-Won Lee, Sung-Nam Lim, Ka-Won Kang, Sang Eun Yoon, Yoo Jin Lee, Hye Jin Kang, Ho Sup Lee, Hyo Jung Kim, Hong Hoe Koo, Ho-Jin Shin, Hyeon-Seok Eom, Jong-Ho Won, Won Seog Kim

Blood (2023) 142 (Supplement 1): 3073.

https://doi.org/10.1182/blood-2023-181809

Published: 2023

Journal Articles

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2023) 142 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2023-184431

Published: 2023

Journal Articles

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Sung-Soo Yoon, Dongyeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yoo Jin Lee, Joseph Clarey, Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2023) 142 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2023-185606

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Transcriptomic signatures associated with deep molecular response to ropeginterferon alfa-2b in polycythemia vera

Clinical significance of earlier CHR achievement and long-term CHR maintenance in polycythemia vera patients treated with ropeginterferon alfa-2b

Rapid JAK2 V617F decline predicts response durability: Kinetics of JAK2 V617F in ropeginterferon alfa-2b treated polycythemia vera

Phase I/II study of zanubrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (ZR-ICE) in Relapsed/Refractory diffuse large B-cell lymphoma: Results of the Phase I portion

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Distinct Factors Influence on Complete Hematological Response Maintenance in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b: From a Phase 2 Study in South Korea

Refining Symptom Response Criteria in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b

Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Retrospective Analysis of Treatment Outcome Differences with and without Autologous Stem Cell Transplantation in Patients with Dialysis-Dependent Multiple Myeloma (DDMM): KMM2304 Study

Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Multicenter Prospective Phase II Study of Rituximab Combined, Bortezomib, Lenalidomide, Dexamethasone Followed By Lenalidomide Maintenance (R-VRD) in Patients with Waldenstrom's Macroglobulinemia (KMM1803)

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only